These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28438936)

  • 21. Evaluating New Compounds to Treat
    Ross BN; Myers JN; Muruato LA; Tapia D; Torres AG
    Front Cell Infect Microbiol; 2018; 8():210. PubMed ID: 30013953
    [No Abstract]   [Full Text] [Related]  

  • 22. High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.
    Lee JW; Kim N; Nam RH; Kim JM; Park JY; Lee SM; Kim JS; Lee DH; Jung HC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7629-36. PubMed ID: 26416863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in situ high-throughput screen identifies inhibitors of intracellular
    Bulterys PL; Toesca IJ; Norris MH; Maloy JP; Fitz-Gibbon ST; France B; Toffig B; Morselli M; Somprasong N; Pellegrini M; Schweizer HP; Tuanyok A; Damoiseaux R; French CT; Miller JF
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18597-18606. PubMed ID: 31439817
    [No Abstract]   [Full Text] [Related]  

  • 24. Antimicrobial resistance in Burkholderia pseudomallei.
    Vorachit M; Chongtrakool P; Arkomsean S; Boonsong S
    Acta Trop; 2000 Feb; 74(2-3):139-44. PubMed ID: 10674642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.
    Dalhoff A; Schubert S; Vente A
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
    Wagenlehner F; Nowicki M; Bentley C; Lückermann M; Wohlert S; Fischer C; Vente A; Naber K; Dalhoff A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the role of Burkholderia pseudomallei K96243 toxins BPSS0390, BPSS0395, and BPSS1584 in persistent infection.
    Ross BN; Micheva-Viteva S; Hong-Geller E; Torres AG
    Cell Microbiol; 2019 Dec; 21(12):e13096. PubMed ID: 31400259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-Phase Bactericidal Mechanism of Silver Nanoparticles against Burkholderia pseudomallei.
    Siritongsuk P; Hongsing N; Thammawithan S; Daduang S; Klaynongsruang S; Tuanyok A; Patramanon R
    PLoS One; 2016; 11(12):e0168098. PubMed ID: 27977746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei.
    Smith MD; Wuthiekanun V; Walsh AL; White NJ
    J Antimicrob Chemother; 1996 Mar; 37(3):611-5. PubMed ID: 9182118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents.
    Thibault FM; Hernandez E; Vidal DR; Girardet M; Cavallo JD
    J Antimicrob Chemother; 2004 Dec; 54(6):1134-8. PubMed ID: 15509614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei.
    Peddayelachagiri BV; Paul S; Makam SS; Urs RM; Kingston JJ; Tuteja U; Sripathy MH; Batra HV
    PLoS One; 2014; 9(3):e90930. PubMed ID: 24614539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro antibiotic susceptibility compliance with efficacy of chemotherapy in infections due to pathogenic Burkholderias].
    Iliukhin VI; Senina TV; Trushkina MN; Shubnikova EV; Antonov IuV; Andropova NV
    Antibiot Khimioter; 2009; 54(7-8):19-23. PubMed ID: 20201399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
    Steward J; Piercy T; Lever MS; Nelson M; Simpson AJ; Brooks TJ
    J Antimicrob Chemother; 2005 Apr; 55(4):523-7. PubMed ID: 15731198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis.
    Casey WT; Spink N; Cia F; Collins C; Romano M; Berisio R; Bancroft GJ; McClean S
    Vaccine; 2016 May; 34(23):2616-21. PubMed ID: 27091689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Co-Trimoxazole against Experimental Melioidosis Acquired by Different Routes of Infection.
    Nelson M; Burton N; Nunez A; Butcher W; Ngugi S; Atkins TP
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0070822. PubMed ID: 36226972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore.
    Sivalingam SP; Sim SH; Aw LT; Ooi EE
    J Antimicrob Chemother; 2006 Nov; 58(5):1102-3. PubMed ID: 16951412
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei.
    Piliouras P; Ulett GC; Ashhurst-Smith C; Hirst RG; Norton RE
    Int J Antimicrob Agents; 2002 May; 19(5):427-9. PubMed ID: 12007851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of BAL30072 against Burkholderia pseudomallei.
    Mima T; Kvitko BH; Rholl DA; Page MG; Desarbre E; Schweizer HP
    Int J Antimicrob Agents; 2011 Aug; 38(2):157-9. PubMed ID: 21596528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of sitafloxacin against Burkholderia pseudomallei.
    Thamlikitkul V; Trakulsomboon S
    Int J Antimicrob Agents; 2011 Oct; 38(4):364. PubMed ID: 21775108
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.
    Kenny DJ; Sefton AM; Brooks TJ; Laws TR; Simpson AJ; Atkins HS
    Int J Antimicrob Agents; 2010 Jul; 36(1):87-9. PubMed ID: 20462743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.